Latest Headlines

Latest Headlines

Delhi High Court tells India's NPPA to ease up on price caps

Ease up, the Delhi High Court said to drug regulators who sent dunning notices to pharmaceutical companies that allegedly did not cooperate with the latest round of price caps that is routinely revised for products under a list of 348 drugs deemed essential.

Some production resumes at Strides Shasun facility following fire that killed one

Strides Shasun has resumed limited production at its Cuddalore API plant in India following a fire last week that killed one worker.

India's Biocon chief says R&D tax breaks essential for investment

As with most corporate chiefs, Biocon's normally would be pleased with India's proposal to lower the nation's corporate tax rate to 25% from 30%. But, if it means eliminating tax exemptions for investments in research and development, Biocon is opposed.

India-EU trade talks back on next year, GVK issue sidelined

India's efforts to smooth over trade disputes with the European Union will lead to a resumption of bilateral talks early next year, but GVK Biosciences will have to be satisfied with watching from the sidelines.

India's gliptin market ready for a shakeup by Zydus at 11 U.S. cents a pill

India's Zydus Cadila could be about to shake up the India market for diabetes drugs with its Nov. 20 launch of Tenglyn (teneligliptin) for controlling hypoglycemia associated with the Type 2 version of the disease.

Indian court says officials can process Reliance package insert for cancer drug

A court in New Delhi has given permission for the Drug Controller General of India to process the application by Reliance Life Sciences for a breast cancer drug package.

India awaits results from new TB trial on drug-resistant forms

As the rest of the world focuses on finding treatments for increasingly drug-resistant forms of tuberculosis, India awaits the outcome of a trial on what would be its first new drug for the disease in 40 years, according to news reports.

India's Supreme Court wants stricter oversight of MSD, GSK HPV clinical trials

Suggesting that India's chief drug regulator may not be doing enough to protect certain volunteers in clinical trials, the Supreme Court ordered the agency to provide adequate oversight, particularly when drugs to treat the human papillomavirus are concerned.

New India patent chief means Lee Pharma's saxagliptin CL app on hold for now

The appointment of a new Controller-General for Patents, Designs and Trademarks in India has delayed the compulsory license application by Lee Pharma, which wants to produce the diabetes drug saxagliptin developed and patented by London-based AstraZeneca, according to a report by The Hindu.

GSK beefing up vaccine business in India

GlaxoSmithKline is making a move to beef up its vaccine business in India and has started the ball rolling with a price cut on its pneumonia vaccine Synflorix and set the stage for two product launches in 2016, according to a report by the  Business Standard.